Alquraini H, et al. - Researchers used pooled data from multicenter clinical trials to investigate the biochemical efficacy of lanreotide depot/Autogel in similar settings. As per the outcomes, 39-42% achieved insulin-like growth factor-1 (IGF-1) control and 31–35% achieved growth hormone (GH) and IGF-1 control in somatostatin-receptor ligand (SRL)-naïve patients receiving lanreotide depot. They found no marked difference in control rates within post-surgery cohorts from those in corresponding de-novo cohorts.